{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:21:45Z","timestamp":1780579305448,"version":"3.54.1"},"reference-count":65,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The KMT2A (MLL1) gene is altered in a variety of hematological malignancies and solid tumors. KMT2A-rearranged (KMT2Ar) AML represents a distinct subtype associated with poor outcomes and high relapse rate despite initial responsiveness to chemotherapy. Methods: A total of 3863 cases of AML peripheral blood samples were analyzed using the FoundationOne Heme combined comprehensive hybrid capture-based DNA and RNA sequencing assay. Results: Of the 3863 AML cases, 521 (13.4%) featured genomic alterations (GAs) in the KMT2A gene, 99.1% of which were large rearrangements (KMT2Ar). A total of 56.9% were males with a median age of 62 years. Of the KMT2Ar cases, there were 43.1% KMT2A duplications, 52.7% fusions, and 4.2% not otherwise specified rearrangements. A total of 0.9% of the KMT2A-altered AML cases were short variant mutations. There were no KMT2A (0%) amplifications or deletions. KMT2Ar cases were associated with increased GA frequencies in FLT3 (27.3% vs. 19.8%; p = 0.0002), KRAS (17.2% vs. 7.8%; p &lt; 0.0001) (overall; 1.1% KRAS G12C), and IDH2 (16.0% vs. 10.4%; p &lt; 0.0001), while KMT2A wild-type AML (KMT2Awt) had significantly increased GA frequencies in RUNX1 (20.7% vs. 15.8%; p = 0.0081), ASXL1 (16.6% vs. 10.5%; p = 0.0003), and TET2 (16.4% vs. 10.1%; p = 0.0002), NPM1 (17.5% vs. 0.2%; p &lt; 0.0001), and TP53 (17.8% vs. 7.9%; p &lt; 0.0001). Conclusions: KMT2A rearrangements are common in AML (13.4% of cases featured KMT2Ar). A total of 99.1% of alterations in KMT2A are large rearrangements, with fusions being the most commonly observed alteration (52.7% of total rearrangements). No amplifications or deletions were seen. This genomic landscape study highlights significant genomic differences between KMT2Ar and KMT2Awt AML patients, which may enrich our understanding of the molecular profile and clusters of mutations in AML.<\/jats:p>","DOI":"10.3390\/cancers18010161","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T09:56:23Z","timestamp":1767347783000},"page":"161","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterizing KMT2A Rearrangement in Acute Myeloid Leukemia: A Comprehensive Genomic Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-2441","authenticated-orcid":false,"given":"Osama","family":"Batayneh","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-5759","authenticated-orcid":false,"given":"Mahmoudreza","family":"Moein","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour Sabiha","family":"Naji","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansy","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupa R.","family":"Mandava","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-0921","authenticated-orcid":false,"given":"Alexandra","family":"Goodman","sequence":"additional","affiliation":[{"name":"Novant Health Zimmer Cancer Institute, Wilmington, NC 28401, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA"},{"name":"Foundation Medicine, Cambridge, MA 02141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5448-4635","authenticated-orcid":false,"given":"Caleb","family":"Ho","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, MA 02141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Marcus","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, MA 02141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Kupakuwana-Suk","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3420-0601","authenticated-orcid":false,"given":"Teresa","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna B.","family":"Ghimire","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/j.semdp.2023.04.002","article-title":"Updates in molecular genetics of acute myeloid leukemia","volume":"40","author":"Kurzer","year":"2023","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1184","DOI":"10.1093\/milmed\/usaf054","article-title":"Innovative Algorithm for Incidence of Leukemia and Lymphoma in the U.S. Military Health Care System","volume":"190","author":"Penney","year":"2025","journal-title":"Mil. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e42030","DOI":"10.1016\/j.heliyon.2025.e42030","article-title":"A novel perspective on survival prediction for AML patients: Integration of machine learning in SEER database applications","volume":"11","author":"Jia","year":"2025","journal-title":"Heliyon"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101533","DOI":"10.1016\/j.beha.2023.101533","article-title":"Cytogenetics and genomics of acute myeloid leukemia","volume":"37","author":"Snaith","year":"2024","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood.2021014309","article-title":"Guiding the global evolution of cytogenetic testing for hematologic malignancies","volume":"139","author":"Akkari","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yahya, D., Stoyanova, M., Hachmeriyan, M., and Levkova, M. (2025). Genomic Evaluation of AML-Main Techniques and Novel Approaches. J. Clin. Med., 14.","DOI":"10.3390\/jcm14165685"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of Acute Myeloid Leukemia Diagnosis and Pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zjablovskaja, P., and Florian, M.C. (2019). Acute Myeloid Leukemia: Aging and Epigenetics. Cancers, 12.","DOI":"10.3390\/cancers12010103"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3324\/haematol.2020.271619","article-title":"Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis","volume":"107","author":"Milan","year":"2022","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Martignoles, J.A., Delhommeau, F., and Hirsch, P. (2018). Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123850"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41375-024-02261-3","article-title":"The KMT2A\/MLL consensus gene structure: A comprehensive update for research and diagnostic implications","volume":"38","author":"Meyer","year":"2024","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrm3230","article-title":"Trithorax group proteins: Switching genes on and keeping them active","volume":"12","author":"Schuettengruber","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"168453","DOI":"10.1016\/j.jmb.2024.168453","article-title":"KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions","volume":"436","author":"Van","year":"2024","journal-title":"J. Mol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Guarnera, L., D\u2019Addona, M., Bravo-Perez, C., and Visconte, V. (2024). KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25169023"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nrc3929","article-title":"Hijacked in cancer: The KMT2 (MLL) family of methyltransferases","volume":"15","author":"Rao","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: From molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2300093","DOI":"10.1200\/PO.23.00093","article-title":"Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response","volume":"7","author":"Moore","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/cncr.34728","article-title":"Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation","volume":"129","author":"Nguyen","year":"2023","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ccell.2018.08.018","article-title":"HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis","volume":"34","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/PPO.0000000000000571","article-title":"Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?","volume":"28","author":"Swaminathan","year":"2022","journal-title":"Cancer J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e70326","DOI":"10.1002\/cam4.70326","article-title":"Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia","volume":"13","author":"Yin","year":"2024","journal-title":"Cancer Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood.V82.12.3705.3705","article-title":"Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II","volume":"82","author":"Super","year":"1993","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-025-02161-5","article-title":"Revumenib: First Approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/10600280251341279","article-title":"Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation","volume":"59","author":"Lynch","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood.2025029556","article-title":"Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML","volume":"146","author":"Othman","year":"2025","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Hoffmeister, L.M., Orhan, E., Walter, C., Niktoreh, N., Hanenberg, H., von Neuhoff, N., Reinhardt, D., and Schneider, M. (2021). Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13194817"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/ijh.ijh_86_24","article-title":"Lysine (K)-specific methyltransferase 2A (KMT2A) rearrangements among Iraqi de novo acute myeloid leukemia","volume":"13","author":"Abdulameer","year":"2024","journal-title":"Iraqi J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1097\/HS9.0000000000000181","article-title":"The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome","volume":"3","author":"Hinai","year":"2019","journal-title":"Hemasphere"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/ijlh.14532","article-title":"The Characteristics and Outcomes of Adult Acute Myeloid Leukemia Patients With KMT2A-Partial Tandem Duplication","volume":"47","author":"Xie","year":"2025","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wei, Q., Hu, S., Xu, J., Loghavi, S., Daver, N., Toruner, G.A., Wang, W., Medeiros, L.J., and Tang, G. (2024). Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms: Associated Cytogenetics, Gene Mutations, Treatment Responses, and Patient Outcomes. Cancers, 16.","DOI":"10.3390\/cancers16244193"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Seto, A., Downs, G., King, O., Salehi-Rad, S., Baptista, A., Chin, K., Grenier, S., Nwachukwu, B., Tierens, A., and Minden, M.D. (2024). Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia. Cancers, 16.","DOI":"10.20944\/preprints202403.0904.v1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1182\/blood-2024-206218","article-title":"Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience","volume":"144","author":"Bawwab","year":"2024","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ng.3371","article-title":"The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias","volume":"47","author":"Baccelli","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1073\/pnas.2014732117","article-title":"Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A","volume":"117","author":"Bill","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e35941","DOI":"10.1002\/cncr.35941","article-title":"KRAS mutation status critically determines the clinical outcome of patients with KMT2A-rearranged acute myeloid leukemia","volume":"131","author":"Wu","year":"2025","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/cam4.5026","article-title":"Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23\/KMT2A rearrangements","volume":"12","author":"Yuen","year":"2023","journal-title":"Cancer Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41467-018-04180-1","article-title":"De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia","volume":"9","author":"Pilheden","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: How can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/hematology.2022000325","article-title":"Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3","volume":"2022","author":"Sahasrabudhe","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1007\/s11033-023-08680-2","article-title":"Molecular and clinical significance of FLT3, NPM1, DNMT3A and TP53 mutations in acute myeloid leukemia patients","volume":"50","author":"Ali","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sahajpal, N.S., Mondal, A.K., Ananth, S., Njau, A., Ahluwalia, P., Jones, K., Ahluwalia, M., Okechukwu, N., Savage, N.M., and Kota, V. (2020). Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0240976"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/161\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:13:21Z","timestamp":1767608001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18010161"],"URL":"https:\/\/doi.org\/10.3390\/cancers18010161","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}